Syndax Pharmaceuticals Inc
Statements
Cash Flow
Syndax Pharmaceuticals Inc (SNDX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -30 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11 | -10 | -13 | -12 | -10 | -13 | -20 | -15 | -18 | -15 | -17 | -13 | -8.5 | -13 | -16 | -21 | -18 | -16 | -23 | -24 | -25 | 101 | -42 | -40 | -29 | -23 | -39 | -35 | -45 | -41 | -84 | -72 | -62 | -57 | -95 | -88 | -71 | -69 | -50 | -30 | -221 | |
| 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | -0.2 | 0.1 | 0.1 | 0.1 | -0.2 | 0.2 | -0.2 | -0.2 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.8 | 0.9 | 1.4 | 1.4 | 1.3 | 1.3 | 1.4 | 1.6 | 1.7 | 1.5 | 1.6 | 1.3 | 1.6 | 1.5 | 1.8 | 2.1 | 3.1 | 2.0 | 2.8 | 3.2 | 3.4 | 3.9 | 3.5 | 3.9 | 4.4 | 4.2 | 6.2 | 8.1 | 8.3 | 8.3 | 8.9 | 9.9 | 12 | 12 | 10 | 14 | 12 | 11 | 12 | 14 | 49 | |
| -0.9 | 6.3 | 1.4 | 1.4 | 1.3 | 5.7 | 1.4 | 1.6 | 1.7 | 1.5 | 1.6 | 1.3 | 1.6 | 1.5 | 1.9 | 2.2 | 3.2 | 2.1 | 2.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.9 | 5.2 | 2.3 | 6.2 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.8 | -0.5 | -1.1 | 0.3 | 3.4 | 5.0 | -1.8 | 1.7 | -2.7 | 2.5 | -3.9 | 1.3 | 2.7 | -0.3 | -2.6 | -6.6 | -1.2 | 2.5 | 2.0 | -4.8 | -8.1 | 1.3 | -8.3 | -6.7 | 2.6 | 14 | -0.5 | 4.7 | 1.6 | 26 | -16 | -10 | 13 | 27 | -17 | -27 | -23 | -12 | -19 | 24 | -30 | |
| 0.1 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | |
| 8.1 | 21 | 11 | -37 | 6.9 | 1.5 | 13 | 19 | 3.5 | 16 | 13 | -19 | 12 | 6.6 | -19 | -79 | 19 | -64 | -29 | 22 | 27 | -60 | 8.2 | -50 | -6.8 | -138 | 20 | 74 | 40 | -16 | -99 | 62 | 87 | -269 | 94 | 42 | 72 | 82 | 38 | -17 | 175 | |
| 1.7 | 54 | 0.1 | 49 | -0.1 | 76 | 0.0 | 0.1 | 9.5 | 6.1 | 28 | 0.0 | 0.1 | 0.1 | 35 | 109 | 1.8 | 139 | 1.0 | 6.0 | 1.7 | 25 | 0.6 | 22 | 7.5 | – | 2.5 | 1.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 20 | 20 | 20 | 20 | – | – | – | – | – | – | -21 | -21 | -21 | -21 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.7 | 0.2 | 0.1 | 49 | 1.0 | 26 | 0.0 | 0.1 | 9.5 | 6.1 | 28 | 0.0 | 0.1 | 0.1 | 55 | 109 | 1.8 | 139 | 1.0 | 6.0 | 1.7 | 110 | 0.6 | 22 | -14 | 164 | 2.5 | 1.3 | 1.9 | 258 | 2.2 | 0.7 | 3.1 | 347 | 0.9 | 0.6 | 6.3 | 5.9 | 7.9 | 253 | 273 | |
| -1.7 | 11 | -1.5 | 0.6 | -2.3 | 14 | -7.2 | 4.2 | -5.5 | 7.1 | 24 | -31 | 3.9 | -6.1 | 20 | 9.0 | 2.7 | 59 | -51 | 3.7 | 3.4 | 151 | -33 | -69 | -49 | 3.0 | -17 | 40 | -2.7 | 201 | -181 | -9.2 | 28 | 21 | -0.1 | -45 | 8.2 | 18 | -4.0 | 206 | 228 | |
| -12 | -10 | -13 | -12 | -10 | -13 | -20 | -15 | -18 | -15 | -17 | -13 | -8.5 | -13 | -16 | -21 | -18 | -16 | -23 | -24 | -25 | 101 | -42 | -40 | -29 | -23 | -39 | -35 | -45 | -41 | -84 | -72 | -62 | -57 | -95 | -88 | -71 | -70 | -50 | -30 | -221 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.